about
Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyWhen to treat patients with relapsed follicular lymphoma.Idelalisib may have the potential to increase radiotherapy side effects.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.Current Treatment of Chronic Lymphocytic Leukemia.Chronic lymphocytic leukaemia genomics and the precision medicine era.Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.A retrospective study on the management of patients with rituximab refractory follicular lymphoma.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.Comparative High-Resolution Transcriptome Sequencing of Lymphoma Cell Lines and de novo Lymphomas Reveals Cell-Line-Specific Pathway Dysregulation.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.Critical molecular pathways in CLL therapy.Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisibIdelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma
P2860
Q29248893-AFE28705-0AE2-4B5D-90EB-5F947758A388Q30238528-6576A25F-8C48-44F4-ADB5-9831D675DA17Q32186978-D08DDFD5-4306-4DD4-8B33-1F7FA70F6B2DQ38818283-62BBE176-CE62-4FA8-A9B0-095E31469752Q38984735-4D7D9100-5318-4973-9A0B-9B8ECF70264AQ39098904-4B384DB4-968A-4B20-B8B1-7F5DEEA17867Q39129372-1DA026F7-DAAB-4103-A024-28CB076A78FFQ39263974-768C56B8-906B-421B-B02F-ABD9AA749F95Q40411526-0DFF5533-E298-4F7F-A4D5-700D0A3816D3Q41994564-8D175AB6-E8DA-4F68-A60D-C5B725197B4AQ46430396-AE749FCD-13A5-4C00-A776-6C9BEF5D1F66Q47300115-708857AC-DB0D-41BC-8324-61BBA54AF95EQ47325778-9C16F861-203F-4D6C-A3F2-5666B11A91D9Q49226138-22488942-44B9-4CDE-ADF2-DC5552F3DDA4Q52576433-87E25E98-8FCE-4DD4-9045-6D55567B6E61Q54982413-56A47F99-2938-475F-97B2-7EED13F3B79BQ55281964-3E74A6B0-4339-46E6-A610-FE96E52B8FF4Q55447785-08AB145B-792D-4C5B-8D34-DA4DB579ABF3Q58729853-1E246559-F40A-4074-BBC7-10B368B3EDF6Q58733788-54CFED41-32C7-4145-AFAF-72F220EBF706
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Idelalisib in the management of lymphoma.
@ast
Idelalisib in the management of lymphoma.
@en
Idelalisib in the management of lymphoma.
@nl
type
label
Idelalisib in the management of lymphoma.
@ast
Idelalisib in the management of lymphoma.
@en
Idelalisib in the management of lymphoma.
@nl
prefLabel
Idelalisib in the management of lymphoma.
@ast
Idelalisib in the management of lymphoma.
@en
Idelalisib in the management of lymphoma.
@nl
P2860
P1433
P1476
Idelalisib in the management of lymphoma
@en
P2093
Nathan H Fowler
P2860
P304
P356
10.1182/BLOOD-2016-02-702761
P407
P577
2016-06-01T00:00:00Z